1. What Is the Companion Diagnostics Market?
The Companion Diagnostics Market covers the in vitro diagnostic tests that are co-developed and co-approved with a targeted therapeutic to identify patients most likely to respond or most at risk of adverse reaction, supplied to oncology and specialty medicine programmes. Oncologists use companion diagnostics to select patients for targeted cancer therapies, directing treatment to those with the specific molecular alteration the drug addresses. The market serves oncology as the primary indication, with companion diagnostics required by regulatory agencies for approved targeted therapies including EGFR inhibitors, HER2-directed therapy, and PD-L1 checkpoint inhibitors. It includes immunohistochemistry assays, in situ hybridisation tests, and next-generation sequencing companion tests, with demand driven by the growth of targeted cancer therapy approvals that require matched diagnostics.
2. Companion Diagnostics Market Size & Forecast
3. Emerging Technologies
- Comprehensive genomic profiling panels reporting hundreds of clinically relevant alterations from a single tissue sample.
- PD-L1 immunohistochemistry assays selecting patients for checkpoint inhibitor immunotherapy.
- FISH and ISH assays detecting HER2 amplification and ALK rearrangement for targeted therapy selection.
- Liquid biopsy ctDNA assays identifying targetable mutations without tissue biopsy for difficult-to-access tumours.
Similar technologies are also transforming adjacent markets. Learn more in our Point Of Care Diagnostics Market.
4. Key Market Opportunity
The largest near-term opportunity in the Companion Diagnostics market lies in oncology centres adopting comprehensive genomic profiling as the primary companion diagnostic approach for multi-drug selection. A second, faster-growing opportunity lies in reference laboratories expanding next-generation sequencing capacity for the growing volume of tumour-profiling requests. As adoption broadens, the addressable opportunity is expanding from early deployments toward wider commercial use, with Europe positioned for the most rapid growth through 2034.
5. Top Companies in the Companion Diagnostics Market
The following organisations hold leading positions in the Companion Diagnostics Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Roche (Foundation Medicine, cobas)
- Abbott
- Qiagen
- Agilent Technologies
- Nanostring Technologies
- Illumina
- Guardant Health
- Dako (Agilent)
- BioNTech Diagnostics
- PGDx
6. Market Segmentation
The Companion Diagnostics Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Technology | ImmunohistochemistryFISH and ISHNext-Generation SequencingPCR |
| By Application | Lung CancerBreast CancerColorectalOther Solid Tumours |
| By End User | Hospital LabReference Lab |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Companion Diagnostics Market trajectory over the forecast period:
Next-Generation Sequencing-Based Companion Diagnostics Are Advancing from Single-Gene to Comprehensive Genomic Profiling.Next-generation sequencing-based companion diagnostics are advancing from single-gene to comprehensive genomic profiling, as the FDA approval of Foundation Medicine's FoundationOne CDx as a multi-gene companion diagnostic enables a single test to report on hundreds of alterations relevant to multiple targeted therapies. This pan-cancer profiling approach allows one test to satisfy companion diagnostic requirements for several drugs simultaneously rather than running sequential single-marker tests. The efficiency and information richness of comprehensive genomic profiling are driving adoption at major oncology centres. Roche's acquisition of Foundation Medicine reflects the strategic importance of this position.
The Proliferation of Targeted Therapies Requiring Companion Diagnostics Creates Growing Demand.The proliferation of targeted therapies requiring companion diagnostics creates growing demand, as each new targeted drug approval either requires an existing companion test or drives development of a new one. The oncology pipeline continues to generate new targeted agents in lung, breast, colorectal, and genitourinary tumours that each require patient selection through a specific biomarker test. This pipeline linkage creates structural growth independent of any single therapeutic class.
Liquid Biopsy Companion Diagnostics Are Expanding the Testing Approach.Liquid biopsy companion diagnostics are expanding the testing approach, as plasma-based ctDNA assays can identify targetable mutations from a blood draw without tissue biopsy. This non-invasive approach supplements tissue testing for patients where biopsy is difficult or where serial monitoring of treatment response is needed.
For related market intelligence, see the In Vitro Diagnostics Market.
8. Segmental Analysis
By technology, the immunohistochemistry segment dominated the Companion Diagnostics Market in 2025, as IHC assays for PD-L1 and HER2 represent the widest-deployed companion diagnostic technology by test volume.
By technology, the next-generation sequencing segment is projected to register the highest CAGR in the Companion Diagnostics Market through 2034, as comprehensive genomic profiling gains regulatory companion approval status, driving the fastest-growing technology category within the market.
9. Regional Analysis
Regional demand patterns across the Companion Diagnostics Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Companion Diagnostics Market in 2025, accounting for the largest share of revenue. Moreover, the United States leads through the largest concentration of FDA-approved targeted therapies with companion diagnostic requirements, the highest oncology drug administration rates, and the most advanced genomic profiling adoption at academic cancer centres. In addition, foundation Medicine and Guardant Health anchor domestic comprehensive profiling. Premium test pricing and high oncology procedure rates sustain revenue leadership.
Highest CAGR Region
Europe is projected to register the highest CAGR in the Companion Diagnostics Market through 2034. The primary driver is EU regulatory alignment toward companion diagnostic co-approval requirements as European Medicines Agency policy converges with FDA precedent, expanding the mandatory companion diagnostic landscape across European oncology. Moreover, European oncology centre adoption of comprehensive genomic profiling is growing. The combination of these demand drivers and an expanding base positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Companion Diagnostics Market was valued at USD 6.25 Bn in 2025 and is projected to reach USD 21.64 Bn by 2034, growing at a CAGR of 14.8% over the 2026–2034 forecast period.
The Companion Diagnostics Market is projected to grow at a CAGR of 14.8% from 2026 to 2034.
North America dominated the Companion Diagnostics Market in 2025, accounting for the largest share of revenue.
The leading companies in the Companion Diagnostics Market include Roche (Foundation Medicine, cobas), Abbott, Qiagen, Agilent Technologies, Nanostring Technologies, Illumina, Guardant Health, Dako (Agilent), BioNTech Diagnostics, PGDx.
Next-generation sequencing-based companion diagnostics are advancing from single-gene to comprehensive genomic profiling.
By technology, the immunohistochemistry segment dominated the Companion Diagnostics Market in 2025, as IHC assays for PD-L1 and HER2 represent the widest-deployed companion diagnostic technology by test volume.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.